Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
March 03 2017 - 7:44AM
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage
biopharmaceutical company focused on developing therapies for
life-threatening rare genetic diseases, today announced President
and CEO, Timothy J. Miller, Ph.D., will present a company overview
and update on recent clinical developments at the upcoming Maxim
Group LLC Biotech Investor and Partnering Conference in Shanghai,
China.
Below are the details regarding the Abeona
Therapeutics Presentation:
Presenter: Timothy J. Miller,
Ph.D.Date: Monday, March 6thTime:
11:45 am CSTLocation: Shanghai, China
Abeona Recent Highlights:
- February 17, 2017: Provided update from ABO-102 Sanfilippo type
A program at WORLDSymposium lysosomal storage disorders conference-
63% +/- 0.5% reduction in the disease-causing sugar (heparan
sulfate GAG) in the central nervous system 6 months post-injection
(n=2)- Continued evidence of biopotency: reduced liver and spleen
volumes, decreased urinary GAGs- Evidence for stabilization or
improvement (average 60%) in several Mullen subdomains at 6-month
timepoint- Adaptive behavior ratings on the Vineland assessment
stabilized- Improved ability to complete individual items on the
Leiter-R non-verbal IQ assessment- Well-tolerated through 650 days
follow up with no Serious Adverse Events (n=4)
- February 1, 2017: Enrolled first high dose subject in ongoing
Phase 1/2 gene therapy clinical trial for Sanfilippo syndrome Type
A (MPS IIIA)
- January 19, 2017: Received Orphan Drug Designation in the
European Union for ABO-101 gene therapy in Sanfilippo syndrome Type
B (MPS IIIB)
- January 3, 2017: Received Orphan Drug Designation in the
European Union for ABO-201 gene therapy program in juvenile Batten
disease (JNCL)
About Abeona: Abeona
Therapeutics Inc. is a leading clinical-stage biopharmaceutical
company developing gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and
ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene
therapies for Sanfilippo syndrome (MPS IIIA and IIIB,
respectively). Abeona is also developing EB-101 (gene-corrected
skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB),
EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene
therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene
therapy for treatment of infantile Batten disease (INCL), and
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302
using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona has a
plasma-based protein therapy pipeline, including SDF Alpha™
(alpha-1 protease inhibitor) for inherited COPD, using its
proprietary SDF™ (Salt Diafiltration) ethanol-free process. For
more information, visit www.abeonatherapeutics.com.
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain
necessary regulatory approvals; the impact of changes in the
financial markets and global economic conditions; our belief that
initial signals of biopotency and clinical activity, which suggest
that ABO-102 successfully reached target tissues throughout the
body, including the central nervous system; our belief that the
data demonstrate an early and robust systemic delivery of ABO-102,
and the increased reductions in CNS GAG support our approach for
intravenous delivery for subjects with Sanfilippo syndromes, and
other risks as may be detailed from time to time in the Company's
Annual Reports on Form 10-K and other reports filed by the Company
with the Securities and Exchange Commission. The Company undertakes
no obligations to make any revisions to the forward-looking
statements contained in this release or to update them to reflect
events or circumstances occurring after the date of this release,
whether as a result of new information, future developments or
otherwise.
Investor Contact:
Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com
Media Contact:
Andre’a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024